Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PHARMASGP HOLDING SE

(PSG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

PharmaSGP Holding SE raises forecast for FY 2021 following completion of acquisition of OTC brand portfolio

09/15/2021 | 12:59pm EST

DGAP-Ad-hoc: PharmaSGP Holding SE / Key word(s): Change in Forecast PharmaSGP Holding SE raises forecast for FY 2021 following completion of acquisition of OTC brand portfolio 15-Sep-2021 / 18:58 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

-----------------------------------------------------------------------------------------------------------------------

Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014

PharmaSGP Holding SE raises forecast for FY 2021 following completion of acquisition of OTC brand portfolio

Gräfelfing, September 15, 2021 - Following the scheduled closing on August 31, 2021 of the agreement signed with the GlaxoSmithKline Group on the acquisition of an OTC portfolio with the brands Baldriparan^(R), Formigran^(R), Spalt^(R) and Kamol^(R) (the "GSK Portfolio"), PharmaSGP Holding SE is adjusting its revenues and earnings guidance for the 2021 financial year. This was decided by the company's Management Board today. Revenues as well as the adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA) of the PharmaSGP Group, which replaces the previous performance indicator "adjusted earnings before interest and taxes (adjusted EBIT)", serve as key performance indicators.

Previously, revenues of between EUR 56 million and EUR 60 million (2020: EUR 63.2 million) were expected for fiscal 2021, excluding any acquisitions, with a stable to slightly positive development of the "Health Brands" category and a declining "Beauty" business as expected. For the adjusted EBIT margin, the company had forecast an increase to between 27% and 30% (2020: 26.1 %); this corresponds to an adjusted EBITDA margin of between 28% and 31% (2020: 26.9 %). Including the revenues and earnings contributions of the GSK portfolio from September 1, 2021 onwards, the Management Board now expects full-year 2021 revenues of between EUR 60 million and EUR 65 million and an adjusted EBITDA margin of between 27 % and 31 %.

Note: The key performance indicators "Adjusted EBIT" and "Adjusted EBITDA" are not key performance indicators under IFRS. The adjustments used to derive adjusted EBITDA correspond to those used for adjusted EBIT. Information on this is available in the PharmaSGP Holding SE Annual Report 2020 on p. 37 (available at https://ir.pharmasgp.com).

-----------------------------------------------------------------------------------------------------------------------

15-Sep-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

-----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      PharmaSGP Holding SE 
              Lochhamer Schlag 21 
              82166 Gräfelfing 
              Germany 
E-mail:       ir@pharmasgp.com 
Internet:     https://pharmasgp.com 
ISIN:         DE000A2P4LJ5 
WKN:          A2P4LJ 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich 
EQS News ID:  1233677 
 
End of Announcement  DGAP News Service 
=------------ 

1233677 15-Sep-2021 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1233677&application_name=news

(END) Dow Jones Newswires

September 15, 2021 12:58 ET (16:58 GMT)

All news about PHARMASGP HOLDING SE
11/16PharmaSGP reporting 34% revenue growth andáincreased profitability in Q3 2021
EQ
09/16PHARMASGP : Product portfolio further expanded and internationalisation driven forward in ..
EQ
09/16PharmaSGP Holding SE Announces Financial Results for the First Half of 2021
CI
09/15PharmaSGP Holding SE Raises Financial Forecast for Fiscal Year 2021
CI
08/31PHARMASGP : GSK Closes Sale of Four OTC Brands to PharmaSGP
MT
08/31PHARMASGP : completes acquisition of OTC brand portfolio (Baldriparan(R), Formigran(R), Sp..
EQ
06/28PHARMASGP HOLDING SE : Notification and public disclosure of transactions by persons
EQ
06/25PHARMASGP : successfully holds first AGM after IPO
EQ
06/20Certain Bearer Shares of PharmaSGP Holding SE are subject to a Lock-Up Agreement Ending..
CI
06/15GLAXOSMITHKLINE : to Sell Four OTC Brands to PharmaSGP in $97 Million Deal
MT
More news
Financials
Sales 2021 61,4 M 69,4 M 69,4 M
Net income 2021 9,30 M 10,5 M 10,5 M
Net Debt 2021 68,6 M 77,6 M 77,6 M
P/E ratio 2021 32,0x
Yield 2021 0,95%
Capitalization 292 M 330 M 330 M
EV / Sales 2021 5,87x
EV / Sales 2022 4,66x
Nbr of Employees 63
Free-Float 22,2%
Chart PHARMASGP HOLDING SE
Duration : Period :
PharmaSGP Holding SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHARMASGP HOLDING SE
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 24,30 €
Average target price 34,50 €
Spread / Average Target 42,0%
EPS Revisions
Managers and Directors
Natalie Weigand Chief Executive Officer
Michael Rudolf Chief Financial Officer
Clemens Fischer Chairman-Supervisory Board
Madlena Hohlefelder Deputy Chairman-Supervisory Board
Axel Rebien Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
PHARMASGP HOLDING SE-6.54%330
ULTA BEAUTY, INC.39.13%22 263
L BRANDS114.90%19 778
E.L.F. BEAUTY, INC.23.34%1 654
SA SA INTERNATIONAL HOLDINGS LIMITED49.59%756
BEAUTY GARAGE INC.38.49%209